Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists watch how dupixent works in everyday asthma care

NCT ID NCT04550962

Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study follows 376 people aged 12 and older who are starting Dupixent for asthma in real-world clinics. Researchers will track their medical history, how they use the drug, and whether it improves lung function and reduces attacks. No new treatment is given—the goal is to learn more about who gets Dupixent and how well it works outside of controlled trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

376 people

The number who actually took part.

Started

Nov 2020

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with asthma initiating DUPIXENT for their asthma according to the prescribing information in effect in each country.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, 12 years or older * Initiating treatment with Dupixent for asthma according to the country-specific prescribing information * Willing and able to comply with the required clinic visits, study procedures and assessments. * Provided signed informed consent Exclusion Criteria: * Patients who have a contraindication to Dupixent according to the country-specific prescribing information * Treatment with Dupixent within 6 months before the baseline visit. Note: for patients who have been treated previously with DUPIXENT a washout period of 6 months is required before Visit 1. * Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing the schedule of visits and assessments * Patients currently participating in any interventional clinical trial which modifies patient care. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Investigational Site Number : 0320001

    Ciudad Autonoma Bs As, C1121ABE, Argentina

  • Investigational Site Number : 0320004

    Santa Fe, 3000, Argentina

  • Investigational Site Number : 0320005

    La Plata, Buenos Aires, B1900BNN, Argentina

  • Investigational Site Number : 0320006

    Villa Rosa, Buenos Aires, 1631, Argentina

  • Investigational Site Number : 0320008

    Ciudad Autonoma Buenos Aires, C1425BEN, Argentina

  • Investigational Site Number : 0320009

    San Miguel de Tucumán, T4000IAI, Argentina

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, 7500692, Chile

  • Investigational Site Number : 1520002

    Quillota, Valparaiso, 2260877, Chile

  • Investigational Site Number : 1700003

    Bucaramanga, Colombia

  • Investigational Site Number : 1700004

    Bogotá, Colombia

  • Investigational Site Number : 1700009

    Barranquilla, 080001, Colombia

  • Investigational Site Number : 3760001

    Kfar Saba, 4428164, Israel

  • Investigational Site Number : 3760003

    Jerusalem, 91120, Israel

  • Investigational Site Number : 3760004

    Ashkelon, 78278, Israel

  • Investigational Site Number : 3760005

    Jerusalem, 91031, Israel

  • Investigational Site Number : 3760006

    Rehovot, 7642001, Israel

  • Investigational Site Number : 3760007

    Tel Aviv, 64239, Israel

  • Investigational Site Number : 3760008

    Ashdod, 7747629, Israel

  • Investigational Site Number : 4140001

    Kuwait City, 00000, Kuwait

  • Investigational Site Number : 4220001

    Beirut, Lebanon

  • Investigational Site Number : 4220002

    Beirut, 11 0236, Lebanon

  • Investigational Site Number : 4220003

    El Achrafiyé, Lebanon

  • Investigational Site Number : 4840003

    Durango, 34000, Mexico

  • Investigational Site Number : 6340001

    Doha, Qatar

  • Investigational Site Number : 6430002

    Stavropol, 355020, Russia

  • Investigational Site Number : 6430004

    Moscow, 115522, Russia

  • Investigational Site Number : 6430005

    Chelyabinsk, 454091, Russia

  • Investigational Site Number : 6430006

    Rostov-on-Don, 344012, Russia

  • Investigational Site Number : 6430007

    Moscow, 105077, Russia

  • Investigational Site Number : 6430008

    Saratov, 410012, Russia

  • Investigational Site Number : 6820001

    Riyadh, 12713, Saudi Arabia

  • Investigational Site Number : 6820002

    Riyadh, 11525, Saudi Arabia

  • Investigational Site Number : 6820004

    Mecca, 24246, Saudi Arabia

  • Investigational Site Number : 6820005

    Jeddah, 23433, Saudi Arabia

  • Investigational Site Number : 7020001

    Singapore, 169308, Singapore

  • Investigational Site Number : 7020002

    Singapore, 119074, Singapore

  • Investigational Site Number : 7840001

    Dubai, 4545, United Arab Emirates

  • Investigational Site Number : 7840002

    Sharjah city, 3499, United Arab Emirates

  • Investigational Site Number : 7840004

    Sharjah city, 00000, United Arab Emirates

  • Investigational Site Number : 7840006

    Abu Dhabi, 0000, United Arab Emirates

  • Investigational Site Number : 7840007

    Dubai, 2, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.